Compare Stocks → The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AKCANASDAQ:AMRNNASDAQ:AUPHNASDAQ:CORTNASDAQ:MDGL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKCAAkcea Therapeutics$18.17$18.16$8.00▼$21.70$1.85B1.45361,806 shsN/AAMRNAmarin$0.88$0.99$0.65▼$1.49$362.75M1.981.26 million shs657,243 shsAUPHAurinia Pharmaceuticals$5.03-1.2%$5.31$4.71▼$12.43$736.10M1.361.28 million shs785,988 shsCORTCorcept Therapeutics$22.48-2.3%$23.89$20.84▼$34.28$2.39B0.48961,519 shs1.09 million shsMDGLMadrigal Pharmaceuticals$204.65-6.3%$244.64$119.76▼$322.67$4.35B-0.47367,475 shs575,483 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKCAAkcea Therapeutics0.00%0.00%0.00%0.00%0.00%AMRNAmarin-0.53%-4.20%+4.11%-30.27%-31.36%AUPHAurinia Pharmaceuticals-1.18%+2.44%+0.80%-37.44%-54.56%CORTCorcept Therapeutics-2.26%-2.26%-8.84%-2.09%+1.03%MDGLMadrigal Pharmaceuticals-6.29%-10.37%-17.35%-11.09%-30.81%The Hard Truth About Investing For Retirement (Ad)Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKCAAkcea TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAMRNAmarin0.4295 of 5 stars1.93.00.00.01.90.00.6AUPHAurinia Pharmaceuticals0.66 of 5 stars3.41.00.00.00.90.00.6CORTCorcept Therapeutics4.6808 of 5 stars3.50.00.04.52.53.33.1MDGLMadrigal Pharmaceuticals4.6886 of 5 stars4.41.00.04.63.14.20.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKCAAkcea TherapeuticsN/AN/AN/AN/AAMRNAmarin1.75Reduce$1.0823.30% UpsideAUPHAurinia Pharmaceuticals2.75Moderate Buy$10.0098.81% UpsideCORTCorcept Therapeutics3.00Buy$39.3074.82% UpsideMDGLMadrigal Pharmaceuticals2.73Moderate Buy$356.7374.31% UpsideCurrent Analyst RatingsLatest CORT, MDGL, AUPH, AMRN, and AKCA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2024CORTCorcept TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.004/22/2024MDGLMadrigal PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform$150.003/20/2024MDGLMadrigal PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$325.00 ➝ $405.003/15/2024MDGLMadrigal PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$405.00 ➝ $425.003/15/2024MDGLMadrigal PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$338.00 ➝ $377.003/15/2024MDGLMadrigal PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$320.00 ➝ $375.003/15/2024MDGLMadrigal PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$351.00 ➝ $397.003/15/2024MDGLMadrigal PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$382.00 ➝ $389.003/15/2024MDGLMadrigal PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$349.00 ➝ $390.003/15/2024MDGLMadrigal PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$337.00 ➝ $410.003/15/2024MDGLMadrigal PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSell ➝ Neutral$155.00 ➝ $270.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKCAAkcea Therapeutics$488.54M3.78$0.51 per share35.54$5.78 per share3.14AMRNAmarin$306.91M1.18N/AN/A$1.35 per share0.65AUPHAurinia Pharmaceuticals$175.51M4.14N/AN/A$2.63 per share1.91CORTCorcept Therapeutics$482.38M4.85$0.94 per share24.01$4.92 per share4.57MDGLMadrigal PharmaceuticalsN/AN/AN/AN/A$20.53 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKCAAkcea Therapeutics$40.77M$0.48N/AN/AN/A-12.34%-8.94%-8.02%N/AAMRNAmarin-$59.11M-$0.14N/AN/AN/A-19.26%-10.47%-6.97%5/1/2024 (Confirmed)AUPHAurinia Pharmaceuticals-$78.02M-$0.54N/A9.15N/A-44.45%-20.10%-14.84%5/2/2024 (Confirmed)CORTCorcept Therapeutics$106.14M$0.9523.6616.90N/A21.86%21.98%17.89%5/1/2024 (Estimated)MDGLMadrigal Pharmaceuticals-$373.63M-$19.94N/AN/AN/AN/A-219.39%-98.75%5/7/2024 (Confirmed)Latest CORT, MDGL, AUPH, AMRN, and AKCA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2024N/AMDGLMadrigal Pharmaceuticals-$6.06N/A+$6.06N/AN/AN/A 5/2/2024N/AAUPHAurinia Pharmaceuticals-$0.17N/A+$0.17N/AN/AN/A 5/1/2024N/AAMRNAmarin-$0.0350N/A+$0.0350N/AN/AN/A 2/29/2024Q4 2023AMRNAmarin-$0.05-$0.01+$0.04-$0.01$72.46 million$74.71 million2/28/2024Q4 2023MDGLMadrigal Pharmaceuticals-$5.26-$5.68-$0.42-$5.68N/AN/A2/15/202412/31/2023AUPHAurinia Pharmaceuticals-$0.16-$0.19-$0.03-$0.19$45.00 million$45.10 million 2/15/2024Q4 2023CORTCorcept Therapeutics$0.25$0.28+$0.03$0.28$129.27 million$135.41 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKCAAkcea TherapeuticsN/AN/AN/AN/AN/AAMRNAmarinN/AN/AN/AN/AN/AAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/ACORTCorcept TherapeuticsN/AN/AN/AN/AN/AMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKCAAkcea TherapeuticsN/A12.1711.78AMRNAmarinN/A2.801.80AUPHAurinia Pharmaceuticals0.205.504.99CORTCorcept TherapeuticsN/A4.394.31MDGLMadrigal Pharmaceuticals0.285.385.38OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKCAAkcea Therapeutics19.27%AMRNAmarin22.25%AUPHAurinia Pharmaceuticals36.83%CORTCorcept Therapeutics93.61%MDGLMadrigal Pharmaceuticals98.50%Insider OwnershipCompanyInsider OwnershipAKCAAkcea Therapeutics1.50%AMRNAmarin1.96%AUPHAurinia Pharmaceuticals4.30%CORTCorcept Therapeutics19.80%MDGLMadrigal Pharmaceuticals23.92%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAKCAAkcea Therapeutics248101.60 millionN/AOptionableAMRNAmarin275410.67 million402.62 millionOptionableAUPHAurinia Pharmaceuticals300144.62 million138.40 millionOptionableCORTCorcept Therapeutics352104.08 million83.48 millionOptionableMDGLMadrigal Pharmaceuticals37619.90 million15.14 millionOptionableCORT, MDGL, AUPH, AMRN, and AKCA HeadlinesSourceHeadlineMadrigal Pharmaceuticals to Unveil First-Quarter Results, Hosts Live Webcastmsn.com - April 25 at 1:07 AMMadrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 6%marketbeat.com - April 24 at 7:14 PMMadrigal Statement on the Passing of Dr. Stephen Harrisonglobenewswire.com - April 24 at 4:00 PMMadrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024finance.yahoo.com - April 23 at 8:19 AMMadrigal Pharmaceuticals (NASDAQ:MDGL) Coverage Initiated by Analysts at Bank of Americaamericanbankingnews.com - April 23 at 3:34 AMUnited Healthcare’s Favorable Insurance Coverage of Rezdiffra Boosts Madrigal Pharmaceuticals Buy Ratingmarkets.businessinsider.com - April 22 at 8:53 PMMadrigal Pharmaceuticals (NASDAQ:MDGL) Earns Underperform Rating from Analysts at Bank of Americamarketbeat.com - April 22 at 8:29 AMKnights of Columbus Asset Advisors LLC Acquires 4,386 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)marketbeat.com - April 21 at 6:39 AMMadrigal Pharmaceuticals Welcomes New Employees with Equity Awardsmsn.com - April 20 at 6:14 AMMadrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price Down 3.3%marketbeat.com - April 17 at 12:20 PMMadrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - April 16 at 4:05 PM7 Stocks Analysts Are Loving Right Now (And You Should Too): April 2024investorplace.com - April 15 at 7:52 AM211,488 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Purchased by AlpInvest Partners B.V.marketbeat.com - April 14 at 8:45 PMMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CMO Rebecca Taub Sells 2,676 Sharesinsidertrades.com - April 11 at 6:37 AMMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Paul A. Friedman Sells 26,270 Shares of Stockinsidertrades.com - April 11 at 6:16 AMMadrigal Pharmaceuticals Launches Rezdiffra, a Pioneer in NASH Treatmentmsn.com - April 10 at 10:34 PM2 Under-the-Radar Growth Stocks to Considermsn.com - April 10 at 12:33 PM2 Under-the-Radar Growth Stocks to Considerfool.com - April 10 at 10:15 AMMoody Aldrich Partners LLC Sells 4,356 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)marketbeat.com - April 10 at 8:54 AMFirst ever MASH drug primed for big impact in USAthepharmaletter.com - April 9 at 4:17 PMMadrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosisfinance.yahoo.com - April 9 at 8:42 AMJames M. Daly Sells 32,489 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stockinsidertrades.com - April 9 at 4:22 AMMadrigal Pharmaceuticals, Inc.cnn.com - April 7 at 1:19 AMMadrigal Pharmaceuticals Awards Equity to New Employees as Inducementmsn.com - April 6 at 8:18 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAkcea TherapeuticsNASDAQ:AKCAAkcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.AmarinNASDAQ:AMRNAmarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Aurinia PharmaceuticalsNASDAQ:AUPHAurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Corcept TherapeuticsNASDAQ:CORTCorcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.Madrigal PharmaceuticalsNASDAQ:MDGLMadrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.